Clinical trials: Risperidone
Psychotic Disorders
Magnetic Seizure Therapy for Psychotic Disorders
This trial aims to evaluate the efficacy and safety of Magnetic Seizure Therapy (MST) as an augmentation of antipsychotic medications for psychosis.
- Trial name
- NCT06581302
- Testing
- Magnetic seizure therapy by Magnetic stimulator, Antipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc)
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Schizophrenia
Study of a Novel Antipsychotic ITI-007 in Schizophrenia
The purpose of this study is to evaluate whether ITI-007 is effective in reducing symptoms associated with schizophrenia in patients who are having an acute worsening of their psychosis.
- Trial name
- NCT01499563
- Testing
- ITI-007, Risperidone
- Where
- 8 sites in United States
- Volunteers
- 335 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation…
- Trial name
- NCT02469155
- Testing
- ITI-007, Risperidone
- Where
- 11 sites in United States
- Volunteers
- 696 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia, Schizoaffective Disorder
High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
The purpose of this study is to look at two doses of long-acting injectable risperidone (Risperdal Consta). The study will use a usual dose of Risperdal Consta (50 mg given every two weeks) or a higher dose (75 mg-100 mg given…
- Trial name
- NCT00539071
- Testing
- long-acting injectable risperidone, long acting injectable risperidone, Conventional Dose Group, long acting injectable risperidone, High Dose Group
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Northwestern University
Schizophrenia
Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia
This is a single ascending dose phase 1 study to evaluate the pharmacokinetics (PK), safety, and tolerability of a single intramuscular (IM) injection of quarterly Risperidone (QUAR) for different formulations and dose strengths…
- Trial name
- QUARTZ (NCT06276361)
- Testing
- Oral risperidone; QUAR F1/2, Dose 1 - Gluteal, Oral risperidone; QUAR F1/2, Dose 2 - Gluteal, Oral risperidone; QUAR F1/2, Dose 3 - Gluteal
- Where
- Jordan
- Volunteers
- 58 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Immunoassay, Antipsychotic
Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone
The purpose of this study is to collect whole blood and plasma venous and capillary samples from participants taking aripiprazole, olanzapine, paliperidone, or risperidone for the development of antipsychotic immunoassays.
- Trial name
- NCT02634463
- Testing
- Aripiprazole, Olanzapine, Paliperidone
- Where
- Belgium
- Volunteers
- 81 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia Disorder
Adjunctive iTBS for First-Episode Schizophrenia
This prospective, randomized, assessor-blinded study investigates the efficacy and safety of adding intermittent theta-burst stimulation (iTBS) to a standard treatment of risperidone and cognitive behavioral therapy (CBT) for…
- Trial name
- NCT07116850
- Testing
- Intermittent Theta-Burst Stimulation (iTBS), Risperidone, Cognitive Behavioral Therapy (CBT)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Hospital of Hebei Medical University
Age 3 to 7 Years, Mild Autism Spectrum
the Effect of Formulation on Anxiety in Autist Childre A Randomized Controlled Trial Assesses Spirulina Syrup Plus Risperidone in Children With Non-idiopathic Autism. Anxiety is Measured Using the SCAS (Parent Version) Via Daily Online Surveys for One Week and Throughout a 3-month Follow-up Period.
The aim of this study is to evaluate the effect of a Spirulina syrup formulation on reducing anxiety in children with non-idiopathic autism.
- Conditions
- Age 3 to 7 Years, Mild Autism Spectrum, no Other Illness or Disorder
- Trial name
- Autism Anxiety (NCT07060872)
- Testing
- Spirulina Syrup, Risperidone
- Where
- Iran
- Volunteers
- 82 people
- Sponsor
- Shahid Sadoughi University of Medical Sciences and Health Services
Schizophrenia, Psychotic Disorders
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
The purpose of the study is to compare effectiveness of paliperidone palmitate (PP: paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP [that is oral paliperidone extended release {ER}, oral…
- Trial name
- DREaM (NCT02431702)
- Testing
- Aripiprazole, Haloperidol, Olanzapine
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia
A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities
The purpose of this study is to evaluate the feasibility of conducting a study of oral risperidone followed by paliperidone palmitate for once monthly (PP1M) and paliperidone palmitate for every 3 months (PP3M) in rwandan…
- Trial name
- NCT03713658
- Testing
- Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., Paliperidone Palmitate 75 mg eq.
- Where
- 3 sites in Rwanda
- Volunteers
- 34 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
The purpose of this study is to assess the long-term symptomatic response (Visit 2 [Week 1] to Visit 14/Week 66 [End of Study {EOS}]) measured by change in the Clinical Global Impressions -Severity for Schizophrenia (CGI-SS) in…
- Trial name
- CASPAR (NCT04940039)
- Testing
- Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., Paliperidone Palmitate 75 mg eq.
- Where
- 5 sites in Rwanda
- Volunteers
- 93 people
- Sponsor
- Janssen-Cilag International NV
Schizophrenia
Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)
This study is a sequential multiple-assignment randomized trial (RCT) of antipsychotic medication treatment in first-episode schizophrenia patients in the real-world settings.Through analysis of treatment efficacy rate and…
- Trial name
- NCT03510325
- Testing
- Phase 1: Olanzapine, Phase 1: Risperidone, Phase 1: Amisulpride
- Where
- 7 sites in China
- Volunteers
- 762 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Schizoaffective Disorder
A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder
Lyndra Therapeutics, Inc., is developing a long-acting oral (LAO) treatment of risperidone (LYN-005) in a capsule dosage form (LYNX® drug delivery platform).
- Trial name
- Starlyng-2 (NCT06878833)
- Testing
- LYN-005 (risperidone), IR Risperidone
- Sponsor
- Lyndra Inc.
Huntington Disease, Chorea
Risperidone for the Treatment of Huntington's Disease Involuntary Movements
The purpose of this study is to assess the safety and benefit of risperidone for the treatment of chorea (involuntary movements) in Huntington's disease.
- Trial name
- NCT04201834
- Testing
- Risperidone, BioStamp nPoint device
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Rochester
Psychosis
Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine
This study will examine the differential relationships between antipsychotic efficacy and changes in dopaminergic and glutamatergic brain metabolism in lumateperone and risperidone treated early psychosis patients.
- Trial name
- Lumafep (NCT05890768)
- Testing
- Lumateperone, Risperidone
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of New Mexico
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant
This is an Open-Label Study in Stable Schizophrenia Patients to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Risperidone to Risperidone Implant (DLP-114).
- Trial name
- DLP-114 (NCT04418466)
- Testing
- Risperidone
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Delpor, Inc.
22q11.2 Deletion Syndrome
Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome
Chromosome 22q11.2 deletion syndrome (22q11DS) is a neurogenetic condition associated with a high risk of psychiatric disorders, including schizophrenia spectrum disorders.
- Trial name
- NCT04639960
- Testing
- Risperdal
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- University of Geneva, Switzerland
Psychosis, Food-drug Interaction
KF2022#3-trial: Effect of Tea and Cola Beverage on Absorption of Risperidone Oral Solution
Risperidone is widely used in the treatment of schizophrenia, bipolar disorder, and aggression associated with moderate or severe Alzheimer's dementia.
- Trial name
- KF2022#3 (NCT06218979)
- Testing
- Risperidone oral solution
- Where
- Finland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Dementia, Behavior
Deprescribing Antipsychotics in Long-Term Care
Aggressive behaviours in long-term care (LTC) is a difficult health care issue to manage. One method that has been over-used is the prescription of antipsychotics for the behaviours and psychological symptoms of dementia (BPSD).
- Trial name
- NCT02958800
- Testing
- Intervention
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- McMaster University
Schizophrenia
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
The purpose of this study was to evaluate the efficacy of ASP4345 on cognitive impairment compared to placebo using change from baseline in MATRICS Consensus Cognitive Battery (MCCB) neurocognitive composite score (excluding…
- Trial name
- NCT03557931
- Testing
- ASP4345, risperidone, quetiapine
- Where
- 27 sites in United States
- Volunteers
- 233 people
- Sponsor
- Astellas Pharma Global Development, Inc.